公司资料
IDEAYA Biosciences 股价、新闻与催化剂
- 股票代码:
- IDYA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
36.54 USD (+0.66%)
收盘价
最后更新: 2026年8月17日
2.45B USD
市值
股价为何变动
As of Aug 17, 2026, IDYA closed up 0.66% at $36.54. No new same-company headline was identified in the current news window.
公司概览
Precision Oncology Portfolio
IDEAYA Biosciences develops targeted oncology therapies using synthetic lethality and biomarker-defined patient selection. Its portfolio combines a late-stage uveal melanoma franchise with antibody-drug conjugates and small molecules directed at genetically defined cancers.
Darovasertib in Metastatic Uveal Melanoma
Darovasertib is a protein kinase C inhibitor being developed with crizotinib. The Phase 2/3 OptimUM-02 trial met its primary endpoint in first-line HLA-A2-negative metastatic uveal melanoma and supports a planned accelerated-approval NDA.
Broader Uveal Melanoma Development
OptimUM-01 evaluates the darovasertib combination in HLA-A2-positive metastatic disease, while OptimUM-09 studies neoadjuvant treatment in primary uveal melanoma. IDEAYA is also planning the Phase 3 OptimUM-11 trial in the adjuvant setting.
ADC Pipeline
IDE849 is a DLL3-targeted topoisomerase-1 antibody-drug conjugate in Phase 1/2 development, with a registrational monotherapy trial planned in DLL3-positive tumors. IDE034 is a bispecific B7H3 and PTK7 topoisomerase-1 ADC in early clinical development.
Synthetic-Lethality Combinations
IDE397 inhibits MAT2A in MTAP-deleted tumors, while IDE892 targets PRMT5. A planned combination cohort will test dual suppression of the methylthioadenosine pathway in biomarker-selected cancers.
未来催化剂
- Complete OptimUM-02 data in a late-breaking oral presentation at ASCO 2026.
- Completion of the darovasertib NDA filing targeted for the second half of 2026.
- Clinical updates from OptimUM-01, OptimUM-09, IDE849 and IDE034 expected in the second half of 2026.
- Initiation of the IDE892-plus-IDE397 Phase 1 combination cohort planned for mid-2026.
- Initiation of a registrational IDE849 monotherapy trial planned by year-end 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。